Last reviewed · How we verify
Suvorexant Low Dose (LD)
Suvorexant is an orexin receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.
Suvorexant is an orexin receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain. Used for Insomnia (sleep onset and sleep maintenance).
At a glance
| Generic name | Suvorexant Low Dose (LD) |
|---|---|
| Also known as | MK-4305 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Orexin receptor antagonist |
| Target | OX1R and OX2R (orexin receptors 1 and 2) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
Suvorexant selectively antagonizes orexin receptors OX1R and OX2R, which are neuropeptide receptors involved in maintaining wakefulness and arousal. By blocking these receptors, the drug reduces the activity of wake-promoting neurons, thereby facilitating sleep onset and maintenance. The low-dose formulation is designed to provide efficacy with potentially reduced side effects compared to standard dosing.
Approved indications
- Insomnia (sleep onset and sleep maintenance)
Common side effects
- Somnolence
- Headache
- Dizziness
- Abnormal dreams
- Worsening insomnia
Key clinical trials
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029) (PHASE3)
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |